福元医药
(601089)
| 流通市值：76.22亿 | | | 总市值：76.22亿 |
| 流通股本：4.80亿 | | | 总股本：4.80亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,710,146,067.1 | 811,169,644.86 | 3,504,445,642.69 | 2,520,605,126.57 |
| 营业收入 | 1,710,146,067.1 | 811,169,644.86 | 3,504,445,642.69 | 2,520,605,126.57 |
| 二、营业总成本 | 1,533,370,517.07 | 719,694,446.91 | 2,991,036,068.12 | 2,120,432,691.61 |
| 营业成本 | 681,028,628.94 | 310,714,712.85 | 1,208,580,165.12 | 858,150,245.81 |
| 税金及附加 | 22,464,288.9 | 9,284,226.49 | 40,870,457.35 | 28,149,405.85 |
| 销售费用 | 551,518,617.95 | 265,104,034.32 | 1,199,310,097.23 | 852,042,091.19 |
| 管理费用 | 74,695,524.43 | 36,664,115.39 | 150,598,562.85 | 109,700,862.91 |
| 研发费用 | 205,121,780.73 | 97,858,133.46 | 403,415,656.85 | 276,839,281.61 |
| 财务费用 | -1,458,323.88 | 69,224.4 | -11,738,871.28 | -4,449,195.76 |
| 其中:利息费用 | 461,775.19 | 246,710.85 | 1,579,732.14 | 1,269,503.11 |
| 其中:利息收入 | 2,487,179.52 | 455,537.43 | 13,576,613.3 | 5,809,443.96 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 11,377,810.15 | 5,171,913.77 | 17,607,903.8 | 15,559,343.77 |
| 资产处置收益 | 803,249.67 | 420,001.28 | 21,837.92 | 217,888.5 |
| 资产减值损失(新) | -6,101,874.66 | -2,196,736.24 | -16,491,237.75 | -5,395,963.39 |
| 信用减值损失(新) | 1,842,748.81 | 1,760,515.09 | -2,879,787.91 | -1,058,878.15 |
| 其他收益 | 17,348,574.93 | 7,275,477.41 | 21,985,777.59 | 13,153,417.64 |
| 四、营业利润 | 202,046,058.93 | 103,906,369.26 | 533,654,068.22 | 422,648,243.33 |
| 加:营业外收入 | 665,564.35 | 468,028.52 | 1,149,796.21 | 909,160.47 |
| 减:营业外支出 | 1,879,961.87 | 317,591.5 | 11,459,499.08 | 5,693,975.46 |
| 五、利润总额 | 200,831,661.41 | 104,056,806.28 | 523,344,365.35 | 417,863,428.34 |
| 减:所得税费用 | 13,123,141.44 | 7,859,331.14 | 52,080,830.35 | 40,073,476.09 |
| 六、净利润 | 187,708,519.97 | 96,197,475.14 | 471,263,535 | 377,789,952.25 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 187,708,519.97 | 96,197,475.14 | 471,263,535 | 377,789,952.25 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 186,196,276.96 | 95,411,871.24 | 469,364,240.73 | 375,340,383.05 |
| 少数股东损益 | 1,512,243.01 | 785,603.9 | 1,899,294.27 | 2,449,569.2 |
| 扣除非经常损益后的净利润 | 170,364,837.56 | 89,500,072.61 | 450,867,655.34 | 361,821,020.81 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.4 | 0.2 | 1 | 0.78 |
| (二)稀释每股收益 | 0.4 | 0.2 | 1 | 0.78 |
| 九、综合收益总额 | 187,708,519.97 | 96,197,475.14 | 471,263,535 | 377,789,952.25 |
| 归属于母公司股东的综合收益总额 | 186,196,276.96 | 95,411,871.24 | 469,364,240.73 | 375,340,383.05 |
| 归属于少数股东的综合收益总额 | 1,512,243.01 | 785,603.9 | 1,899,294.27 | 2,449,569.2 |
| 公告日期 | 2026-08-15 | 2026-04-25 | 2026-04-14 | 2025-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |